MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT) a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that management is scheduled to present an overview of the company's business at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 17, 2017 at 1:00pm PT at Encore at Wynn, Las Vegas, Nev.
A webcast of the presentation will be available online from the Investor Relations page of the company’s website at www.intersectENT.com. The webcast replay will be available for approximately one month.
About Intersect ENT
Intersect ENT is dedicated to transforming the landscape of care for patients with ear, nose and throat conditions. The company’s PROPEL® family of dissolvable steroid releasing sinus implants are clinically proven to improve outcomes for chronic sinusitis patients undergoing sinus surgery. In addition, Intersect ENT is continuing to expand its portfolio of products based on the company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost effective care.
Intersect ENT: Delivering Innovation. Where It’s Needed.
For additional information on the company or the products including risks and benefits please visit www.IntersectENT.com.
Intersect ENT® and PROPEL® are registered trademarks of Intersect ENT, Inc.